Medifast’s third quarter results were marked by a positive market response, as the company’s revenue slightly exceeded Wall Street’s expectations despite a substantial year-over-year decline. Management attributed the performance to the successful rollout of the Trilogy brand and related products, which have begun to gain traction among coaches and clients. CEO Nicholas Johnson emphasized that improvements in coach productivity and engagement, alongside investments in new training and compensation systems, have helped stabilize the business amid ongoing shifts in the weight management and metabolic health markets. Johnson noted, “Coach productivity improved year over year for the fourth consecutive quarter, to 54% in Q3 and grew an estimated 8% sequentially.”
Is now the time to buy MED? Find out in our full research report (it’s free for active Edge members).
Medifast (MED) Q3 2026 highlights:
- Revenue $72.05 million vs S&P analysts’ estimates of $71.3 million (19.4% year-on-year decline, 1% beat)
- EPS (GAAP) -$1.57 vs analyst estimates of -$0.35 (significant miss)
- Revenue guidance $65 million at the midpoint for Q4 2026, above analyst estimates of $64.1 million
- GAAP EPS guidance $0.13 at the midpoint for Q4 2026, beating analyst estimates by 204%
- EBITDA guidance $12 million at the midpoint for the full year, above analyst estimates of $4.4 million
- Operating margin -26.9%, down from -4.6% in the same quarter last year
- Market capitalization $129.1 million
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our top 5 analyst questions from Medifast’s Q3 earnings call
-
**James Salera (Stephens)**asked about coach engagement and response to the Trilogy brand and operational changes. CEO Nicholas Johnson explained that engagement has been high, with coaches embracing the new compensation plan and unified training system designed to improve productivity.
-
**James Salera (Stephens)**questioned how Medifast’s coaches are competing with the rise of GLP-1 medications and AI-driven weight loss programs. Johnson said coaches are shifting conversations from simply “weight lost” to “quality of weight lost,” emphasizing the preservation of lean mass and metabolic health.
-
**James Salera (Stephens)**inquired about spending differences between clients using GLP-1 medications and those not. CFO James Maloney responded that while they have some anecdotal data from surveys, they do not centrally track this information by customer order.
-
**James Salera (Stephens)**asked about further SG&A cost reduction opportunities. Maloney said the company continues to focus on removing non-growth-related costs and expects further leverage as automation and AI initiatives mature.
-
No additional analyst questions on the call.
Catalysts in upcoming quarters
In the upcoming quarters, StockStory analysts will track (1) the pace of adoption and retention for Trilogy system products and related client engagement, (2) further improvements in coach productivity and stabilization or growth in the active coach base, and (3) measurable cost efficiencies from Project Catalyst and AI integration. Progress in these areas will be crucial for Medifast’s path to sustainable profitability and market share gains in the metabolic health category.
Medifast currently trades at $12.50, up from $11.85 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free).
The best stocks for high-quality investors
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.
